$NTRA

Sheena Jonathan sold $330K of NTRA (indirect holdings)

Sheena Jonathan sold 1,500 indirectly-held shares of Natera, Inc. (NTRA) at an average of $219.87 ($218.14–$222.14, $0.33M total) across 9 trades on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Sheena Jonathan
Published Jun 23, 2026, 1:05 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 23, 2026, 1:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$NTRA
Neutral
high confidence
Mentioned
$NTRA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NTRANeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale amount ($329,809.76) and that it was executed under a pre-arranged Rule 10b5-1 plan; no other company-specific developments are provided.

02

Market read

Primarily a sentiment/positioning datapoint for NTRA; not a fundamental catalyst by itself.

03

What to watch

The filing is indirect holdings and multi-trade execution; without context on total insider activity or remaining plan size, directional inference is limited.

Relevance 3/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-06-22 for trades dated 2026-06-17)

Background

The article is a SEC Form 4 insider transaction disclosure for Natera, Inc. (NTRA).

Company-level read

Ticker impact

$NTRANeutralHigh confidence
Context

Natera director Sheena Jonathan sold about $329.8K of NTRA shares via an open-market sale under a 10b5-1 plan on 2026-06-17.

Expected impact

Low likelihood of a sustained price move; any impact is likely short-lived unless paired with other new fundamentals.

Evidence & confidence

This is a Form 4 insider transaction with a stated pre-arranged 10b5-1 plan and no accompanying company-specific news (earnings, guidance, deal, or regulatory action).

Market effects

Minimal; single-company insider sale without sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale is under a 10b5-1 plan, it may not reflect bearish expectations; traders may discount it entirely.

Key entities

  • Natera, Inc.

    Issuer of the Form 4 insider transaction; director Sheena Jonathan sold shares under a 10b5-1 plan.

  • Sheena Jonathan

    Director reporting an indirect open-market sale of 1,500 shares across nine trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NTRAMedAI 8/10

Natera, Inc.: Signatera Genome with Phased and Structural Variants Highlighted in ESMO Presidential Symposium, Supporting the Critical Role of MRD-Guided Treatment in Bladder Cancer

Natera (NTRA) presented data from the ESMO Congress 2026, showcasing its Signatera assay in 25 abstracts, including 9 oral presentations. The VOLGA trial in bladder cancer showed that Signatera ctDNA dynamics predicted event-free survival, with persistently negative patients having a 24-month EFS rate of 91%. Additional studies in lung, endometrial, and breast cancer were also highlighted, demonstrating the potential of ctDNA testing in guiding treatment decisions.

$NTRAMed

Natera technology featured in 25 abstracts at ESMO congress

Natera Inc. (NTRA) presented cancer study results at the ESMO Congress 2026, with its technology featured in 25 abstracts. Key findings included high event-free survival rates in bladder cancer, high ctDNA detection in lung cancer, and predictive value in endometrial cancer. Studies also covered colorectal and gastroesophageal cancers.

$NTRALow

Natera, Inc. (NTRA) ctDNA Dynamics Predict EFS in MIBC

Natera (NTRA) reported phase III VOLGA trial data showing Signatera ctDNA dynamics predict event-free survival in MIBC, with 24-month EFS rates of 91% for persistently negative, 81% for cleared pre-surgery, and 55% for persistently positive. The company noted this as late-cycle validation for Signatera's role in MRD for bladder cancer.

$NTRAMed

Natera stock price target raised to $430 by BTIG on revenue outlook

BTIG raised its price target on Natera (NTRA) to $430 from $320, citing strong revenue growth expectations. The firm anticipates a 7% revenue beat in Q3 and projects 318,000 Signatera tests, up 57% YoY. Natera's stock is up 77% YTD and 111% over the past year, but is considered overvalued by InvestingPro. Recent Q2 revenue of $753M exceeded expectations, and multiple analysts have raised price targets.